Antiproliferative Activity of Gold(III) Complexes with Esters of Cyclohexyl-Functionalized Ethylenediamine-N,N’-Diacetate

Pantelić, Nebojša; Stanojković, Tatjana P.; Zmejkovski, Bojana B.; Kaluđerović, Goran N.; Sabo, Tibor J.

doi:10.1515/sjecr-2017-0067

Abstract

Six gold(III) complexes with esters of cyclohexyl-functionalized ethylenediamine-N,N’-diacetate, general formula [AuCl₂{(S,S)-R₂eddch}]PF₆, [(S,S)-eddch = (S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoate, R = Me, Et, n-Pr, n-Bu, i-Bu, i-Am, 1–6, respectively], were tested against cancer cell lines such as human melanoma Fem-x, human colon carcinoma LS174T and non-small cell lung carcinoma A549 as well as a non-cancerous human embryonic lung fibroblasts MRC-5 using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay with the aim of assessing in vitro antitumoral activity and selectivity. All investigated complexes showed lower cytotoxicity and better or similar selectivity in comparison to cisplatin, used as reference compound. Complex [AuCl₂{(S,S)-(i-Am)₂eddch}]PF₆ (6) demonstrated the highest activity against Fem-x (IC₅₀ = 14.98 ± 0.34 μM). Additionally, the same complex expressed 4.5 times higher selectivity than cisplatin.

References

1. Haque, M. U., Ferdiousi, N. & Sajon, S. R. (2016). Anticancer agents derived from plant and dietary sources: a review. International Journal of Pharmacognosy 32, 55–66.
Search in Google Scholar Back to article
2. Reedijk, J. (2009). Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design. Eur. J. Inorg. Chem. 10, 1303–1312.10.1002/ejic.200900054
Search in Google Scholar Back to article
3. Coluccia, M. & and Natile, G. (2007). Trans-platinum complexes in cancer therapy. Anti-Cancer Agents Med. Chem. 7, 111–123.10.2174/18715200777931408017266508
Search in Google Scholar Back to article
4. Wang, X. Y. & Guo, Z. J. (2008). Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents. Dalton Trans. 1521–1532.10.1039/B715903J18335133
Search in Google Scholar Back to article
5. Kapoor, L.D. (1990). Handbook of Ayurvedic Medicinal Plants, Boca Raton, Florida, CRC Press, 416–417.
Search in Google Scholar Back to article
6. Hassan, M, Watari H., Almaaty, A. A., Yusuke Ohba, Y. & Sakuragi, N. (2014). Apoptosis and Molecular Targeting Therapy in Cancer. BioMed Res. Int., Article ID 150845, 23 pp.10.1155/2014/150845407507025013758
Search in Google Scholar Back to article
7. Olszewski, U. & Hamilton, G. (2010). A better platinum-based anticancer drug yet to come? Med. Chem. 10, 293–301.10.2174/187152010791162306
Search in Google Scholar Back to article
8. Weiss, R. B. & Christian, M. C. (1993) New Cisplatin Analogues in Development. Drugs 46, 360–37710.2165/00003495-199346030-000037693428
Search in Google Scholar Back to article
9. Ott, I. & Gust, R. (2007). Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Med. Chem. 7, 95–110.10.2174/18715200777931407117266507
Search in Google Scholar Back to article
10. Williams, R. (2011). Discontinued drugs in 2010: oncology drugs. Expert. Opin. Invest. Drugs 20, 1479–1496.10.1517/13543784.2011.62369721955127
Search in Google Scholar Back to article
11. Van den Berg, J. H., Beijnen, J. H., Balm, A. J. M. & Schellens, J. H. M. (2006). Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat. Rev. 32, 390–397.10.1016/j.ctrv.2006.04.01116781082
Search in Google Scholar Back to article
12. Pabla, N. & Dong, Z. (2008). Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73, 994–1007.10.1038/sj.ki.500278618272962
Search in Google Scholar Back to article
13. McWhinney, S. R., Goldberg, R. M. & McLeod, H. L. (2009). Platinum neurotoxicity pharmacogenetics. Mol. Cancer Ther. 8, 10–16.10.1158/1535-7163.MCT-08-0840265182919139108
Search in Google Scholar Back to article
14. Gómez-Ruiz, S., Maksimović-Ivanić, D., Mijatović, S. & Kaluđerović, G. N. (2012). On the Discovery, Biological Effects, and Use of Cisplatin and Metallocenes in Anticancer Chemotherapy. Bioinorg. Chem. Appl. article ID 140284, 1–14.10.1155/2012/140284340152422844263
Search in Google Scholar Back to article
15. Kaluđerović, G. N. & Paschke, R. (2011). Anticancer metallotherapeutics in preclinical development. Curr. Med. Chem. 18, 4738–4752.10.2174/09298671179753530821919843
Open DOI Search in Google Scholar Back to article
16. Koberle, B., Tomicic, M. T., Usanova, S. & Kaina, B. (2010). Cisplatin resistance: preclinical findings and clinical implications. Biochim. Biophys. Acta 1806, 172–182.10.1016/j.bbcan.2010.07.00420647037
Search in Google Scholar Back to article
17. Lakomska, I., Fandzloch, M., Muziol, T., Liz, T. & Jezierska, J. (2013). Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(III) complexes with bulky triazolopyrimidine ligands. Dalton Trans. 42, 6219–6226.10.1039/c2dt32216a23328694
Search in Google Scholar Back to article
18. Matesans, A. I., Leitao, I. & Souza, P. (2013). Palladium(II) and platinum(II) bis(thiosemicarbazone) complexes of the 2,6-diacetylpyridine series with high cytotoxic activity in cisplatin resistant A2780cisR tumor cells and reduced toxicity. J. Inorg. Biochem. 125, 26−31.10.1016/j.jinorgbio.2013.04.00523685347
Search in Google Scholar Back to article
19. Smolenski, P., Jaros, S. W., Pettinari, C., Lupidi, G., Quassinti, L., Bramucci, M., Vitali, L. A., Petrelli, D., Kochel, A. & Kirillow, A. M. (2013). New water-soluble polypyridine silver(I) derivatives of 1,3,5-triaza-7-phosphaadamantane (PTA) with significant antimicrobial and antiproliferative activities. Dalton Trans. 42, 6572−6581.10.1039/c3dt33026e23474654
Search in Google Scholar Back to article
20. Bertrand, B., Bodio, E., Richard, P., Picquet, M., Gendre, P. L. & Casini, A. (2015) Gold(I) N-heterocyclic carbene complexes with an “activable” ester moiety: possible biological applications. J. Organomet. Chem. 775, 124–129.10.1016/j.jorganchem.2014.03.020
Search in Google Scholar Back to article
21. Best, S. L. & Sadler, P. J. (1996) Gold drugs: mechanism of action and toxicity. Gold Bull. 29, 87–93.10.1007/BF03214741
Open DOI Search in Google Scholar Back to article
22. Pantelić, N., Zmejkovski, B. B., Trifunović-Macedoljan, J., Savić, A., Stanković, D., Damjanović, A., Juranić, Z., Kaluđerović, G. N. & Sabo, T. J. (2013). Gold(III) complexes with esters of cyclohexyl-functionalized ethylenediamine-N,N’-diacetate. J. Inorg. Biochem. 128, 146–153.10.1016/j.jinorgbio.2013.08.00223988849
Search in Google Scholar Back to article
23. Pantelić, N., Stanojković, T. P., Zmejkovski, B. B., Sabo, T. J. & Kaluđerović, G. N. (2015). In vitro anticancer activity of gold(III) complexes with some esters of (S,S)-ethylenediamine-N,N’-di-2-propanoic acid. Eur. J. Med. Chem. 90, 766–774.10.1016/j.ejmech.2014.12.01925528331
Search in Google Scholar Back to article
24. Berners-Price, S. J. & Filipovska, A. (2011). Gold compounds as therapeutic agents for human diseases. Metallomics 3, 863–873.10.1039/c1mt00062d21755088
Search in Google Scholar Back to article
25. Nardon, C. & D. Fregona, D. (2016). Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics. Curr. Top. Med. Chem. 16, 360–380.10.2174/1568026615666150827094500
Search in Google Scholar Back to article
26. Warżajtis, B., Glišić, B. Đ., Savić, N. D., Pavic, A., Vojnovic, S., Veselinović, A., Nikodinovic-Runic, J., Rychlewska, U. & Djuran, M. I. (2017). Mononuclear gold(III) complexes with l-histidinecontaining dipeptides: tuning the structural and biological properties by variation of the N-terminal amino acid and counter anion. Dalton Trans. 46(8), 2594–2608.10.1039/C6DT04862E
Search in Google Scholar Back to article
28. Berners-Price S. J. (2011). Gold-based therapeutic agents: a new perspective, in Bioinorganic Medicinal Chemistry, ed. E. Alessio, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. DOI:10.1002/9783527633104.ch710.1002/9783527633104.ch7
Open DOI Search in Google Scholar Back to article
29. Abbate, F., Orioli, P., Bruni, B., Marson, G. & Messori, L. (2000). Crystal structure and solution chemistry of the cytotoxic complex 1,2-dichloro(o-phenanthroline) gold(III) chloride. Inorg. Chim. Acta 311, 1–5.10.1016/S0020-1693(00)00299-1
Search in Google Scholar Back to article
30. Bertrand, B. & and Casini, A. (2014). A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds. Dalton Trans. 43, 4209–4219.10.1039/C3DT52524D
Search in Google Scholar Back to article
31. Gabbiani, C., Casini, A. & Messori, L. (2007). Gold(III) compounds as anticancer drugs. Gold Bull. 40, 73–81.10.1007/BF03215296
Search in Google Scholar Back to article
32. Wang, Y., He, Q., Sun, R., Che, C. M. & Chiu, J. F. (2005). Gold porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res. 65, 11553–11564.10.1158/0008-5472.CAN-05-2867
Search in Google Scholar Back to article
33. Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini A. & Messori, L. (2009). Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev. 253, 1692–1707.10.1016/j.ccr.2009.02.026
Search in Google Scholar Back to article
34. Petrović, V., Petrović, S. Joksić, G., Savić, J., Čolović, M., Cinellu, M. A., Massai, L., Messori L. & Vasić, V. (2014). Inhibition of Na⁺/K⁺-ATPase and cytotoxicity of a few selected gold(III) complexes. J. Inorg. Biochem. 140, 228–235.10.1016/j.jinorgbio.2014.07.015
Search in Google Scholar Back to article
35. Pantelić, N., Stanković, D. M., Zmejkovski, B. B., Kaluđerović, G. N. & Sabo, T. J. (2016). Electrochemical properties of some gold(III) complexes with (S,S)-R2edda-type ligands. Int. J. Electrochem. Sci. 11, 1162–1171.10.1016/S1452-3981(23)15913-X
Search in Google Scholar Back to article
36. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63.10.1016/0022-1759(83)90303-4
Open DOI Search in Google Scholar Back to article
37. Ohno, M. & Abe, T. (1991). Rapid colorimetric assay for the quantification of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6). J. Immunol. Methods 145, 199–203.10.1016/0022-1759(91)90327-C
Search in Google Scholar Back to article

Antiproliferative Activity of Gold(III) Complexes with Esters of Cyclohexyl-Functionalized Ethylenediamine-N,N’-Diacetate

Abstract

Paradigm

My account